Retatrutide + Cagrilintide

Buy Retatrutide + Cagrilintide Online

Retatrutide + Cagrilintide brings together two highly interesting metabolic peptides. Retatrutide targets GLP-1, GIP, and glucagon receptors, while cagrilintide acts through the amylin pathway. Together, they have generated interest in appetite regulation, body-weight research and metabolic health.

Product Information

Retatrutide is a triple receptor agonist currently being studied for obesity and metabolic disease. Cagrilintide is a long-acting amylin analogue. Research on cagrilintide combinations has demonstrated meaningful effects on body weight and metabolic markers, although Retatrutide + Cagrilintide itself should not be confused with the extensively studied CagriSema combination of cagrilintide + semaglutide.

How It Works

Retatrutide activates GLP-1, GIP, and glucagon receptors, influencing appetite, glucose metabolism, and energy expenditure. Cagrilintide works through amylin-related pathways involved in satiety and food intake. The combination therefore targets several different signals involved in energy balance.

Potential Benefits

1. Appetite Control

Both compounds are associated with pathways that influence hunger and satiety. This makes the combination particularly interesting for research into reduced food intake and long-term appetite regulation.

2. Weight-Management Research

Retatrutide has produced substantial body-weight reductions in clinical trials, while cagrilintide has independently demonstrated weight-management potential. Their different mechanisms make the combination an interesting area of metabolic research.

3. Metabolic Health

Retatrutide has demonstrated improvements in several metabolic markers during clinical studies. Cagrilintide adds another pathway involved in energy balance and metabolic regulation.

4. Multi-Pathway Research

The combination allows researchers to examine incretin, glucagon and amylin signaling together. This multi-target approach is one of the most interesting aspects of modern obesity-peptide research.

Dosage

There is no established clinical dosage for the Retatrutide + Cagrilintide combination. Published dosing data for the individual compounds and for cagrilintide/semaglutide combinations should not be treated as validated dosing for this specific blend.

Side Effects

Potential effects include nausea, vomiting, diarrhea, constipation, reduced appetite, and other gastrointestinal symptoms.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. PMID: 37366315. PubMed
2. Buse JB, Bajaj H, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes & Endocrinology. 2026. PMID: 42251859. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to access instructions on how to make a payment.

How to Pay